ASH 2023 | Prognostic significance of molecular MRD in NPM1-mutated AML treated with venetoclax-based therapy
Jad Othman, MBBS, King’s College and Guy’s & St Thomas’ NHS Foundation Trust, London, UK, highlights the prognostic significance of molecular measurable residual disease (MRD) in patients with NPM1-mutated acute myeloid leukemia (AML) treated in the first line with non-intensive venetoclax-based therapy. MRD status serves as a strong predictor of outcomes, particularly bone marrow MRD negativity, by the end of the 4th cycle of treatment. The next steps include determining whether those patients reaching MRD negativity can safely terminate treatment. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
